Ha ha .......Bristol-Myers Squibb paid $74 billion for its acquisition of Celgene and gemcitabine is owned by Lilly who's market cap is in excess of USD $220 billion. And the beauty about these TWO drugs is that they are ALREADY in use and been thoroughly tested in Human Trials making it more likely that AMP945 being fast tracked if successful in co use commercialization.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
